Director of Research Programs in Global Health and Associate Professor of Medicine
Infectious Disease
Dr. Tawanda Gumbo, MD
|
|
Give Review
Tawanda Gumbo, MD practices Infectious Disease. He graduated from University of Zimbabwe Huggins School of Medicine. Tawanda Gumbo, MD is also a published physician. He has 72 publication published. The most recent publication is: Development and application of genetic probes for detection of Enterocytozoon bieneusi in formalin-fixed stools and in intestinal biopsy specimens from infected patients. He accepts Medicare.
Publications
- Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
- Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
- Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
- Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
- Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease.
- In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos.
- Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.
- Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis.
- Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
- The pyrazinamide susceptibility breakpoint above which combination therapy fails.
- Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis.
- Thioridazine Exhibits Wobbly Pharmacokinetic-Pharmacodynamic Parameters During Treatment of Tuberculosis: A Theoretical Basis for Shorter Duration Curative Monotherapy...
- Reply to Moonan and Weis, Nunn and Phillips, and Seaworth et al.
- Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes.
- A meta-analysis of self-administered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients.
- Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures Beyond 2/3 or 3/4.
- Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
- Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs.
- Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of anti-tuberculosis therapy.
- Response to: Dried Blood Spot analysis combined with limited sampling models can advance TDM of TB drugs.
- Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.
- Dysentery in patients infected with human immunodeficiency virus in Zimbabwe: an emerging role for Schistosoma mansoni and Escherichia coli O157?
- Cryptococcus myelitis: atypical presentation of a common infection.
- Recurrent pneumonia from an ileobronchial fistula complicating Crohn's disease.
- Confirmation of transmission of Enterocytozoon bieneusi in South Africa.
- Enterocytozoon bieneusi infection in patients without evidence of immunosuppression: two cases from Zimbabwe found to have positive stools by PCR.
- Aspergillus valve endocarditis in patients without prior cardiac surgery.
- Candida (Torulopsis) glabrata septic arthritis.
- Candida glabrata Fungemia. Clinical features of 139 patients.
- Intestinal parasites in patients with diarrhea and human immunodeficiency virus infection in Zimbabwe.
- Microsporidia infection in transplant patients.
- Development and application of genetic probes for detection of Enterocytozoon bieneusi in formalin-fixed stools and in intestinal biopsy specimens from infected patients.
- Cyclospora: update on an emerging pathogen.
- Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in Zimbabwe.
- Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome.
- Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
- Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Myc...
- Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.
- New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic vari...
- Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.
- Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antitubercu...
- Anidulafungin in the treatment of invasive fungal infections.
- Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy.
- Population pharmacokinetics of micafungin in adult patients.
- Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
- Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
- Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
- Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
- Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
- Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
- Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
- Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
- The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
- Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
- Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
- Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical ...
- Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon.
- AIDS orphans.
- Case report. Nattrassia mangiferae endophthalmitis.
- Reply to "pharmacokinetic mismatch of tuberculosis drugs".
- Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.
- Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
- Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm f...
- Fractal geometry and the pharmacometrics of micafungin in overweight, obese and extremely obese people.
- In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
- A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.
- Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.
- In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.
- An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
- Meningeal tuberculosis: high long-term mortality despite standard therapy.
- Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Cleveland Clinic Foundation -
Case Western Reserve University - MetroHealth -
University of Zimbabwe Huggins School of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Parkland Health & Hospital System -
University Health System
Drug Facts
| NPI NUMBER | 1255323317 | |
| NPPES Provider LastName | GUMBO | |
| NPPES Provider FirstName | TAWANDA | |
| NPPES Provider ZIPCode | 753909113 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 22.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255323317 |
| Last Name Of The Provider | GUMBO |
| First Name Of The Provider | TAWANDA |
| View All |
Similar Doctors
|
Dr. Devak G. Desai, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Dhiraj K. Kotwal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Takaaki Wada, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Aarthi Narasimhan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ceres T. Tiu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison M. Liddell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William L. Sutker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditi Swami, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason W. Gillman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzanne Y. Wada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher J. Bettacchi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Meenakshi S. Prabhakar, MD
This Doctor is OpenDoctor Recommended.
|